Reproductive Endocrinology 

About: Reproductive Endocrinology is an academic journal published by Publishing House TRILIST. The journal publishes majorly in the area(s): Pregnancy & Medicine. It has an ISSN identifier of 2309-4117. It is also open access. Over the lifetime, 693 publications have been published receiving 2696 citations. The journal is also known as: Reproduktivna endokrinologìâ & Reproductive endocrinology.

Sexually transmitted diseases treatment guidelines (2015)

Abstract: Дані рекомендації щодо лікування осіб, які мають або піддаються ризику захворювань, що передаються статевим шляхом (ЗПСШ), були оновлені Центрами з контролю і профілактики захворювань США після консультації з групою фахівців у сфері ЗПСШ, які зустрілися в Атланті навесні 2013 р. Це оновлена версія Керівництва з лікування ЗПСШ від 2010 р. В оновленій версії керівництва обговорюються: 1) альтернативні схеми лікування Neisseria gonorrhoeae; 2) застосування методів ампліфікації нуклеїнових кислот для діагностики трихомоніазу; 3) альтернативні способи лікування гострих кондилом; 4) роль Mycoplasma genitalium у розвитку уретритів/цервіцитів і наслідки, пов’язані з лікуванням; 5) оновлені рекомендації з консультування та вакцинації проти вірусу папіломи людини; 6) менеджмент пацієнтів-транссексуалів; 7) щорічне тестування на гепатит С осіб із ВІЛ-інфекцією; 8) оновлені рекомендації з діагностичної оцінки уретриту; 9) повторне тестування з метою виявлення нового інфікування. Дане керівництво можуть використовувати лікарі та інші медичні працівники для надання допомоги з профілактики та лікування ЗПСШ.

Рекомендации международного общества по менопаузе в отношении здоровья женщин зрелого возраста и менопаузальной гормональной терапии, 2016

Abstract: The International Menopause Society (IMS) has produced these new 2016 recommendations on women’s midlife health and menopause hormone therapy to help guide health-care professionals in optimizing their management of women in the menopause transition and beyond. The term menopause hormone therapy has been used to cover therapies including estrogens, progestogens and combined regimens. Menopausal hormone therapy today is the most effective treatment for vasomotor symptoms and urogenital atrophy.For the first time, the 2016 International Menopause Society recommendations now include grades of recommendations, levels of evidence and ‘good practice points’, in addition to section-specific references. Where possible, the recommendations are based on and linked to the evidence that supports them, unless good-quality evidence is absent. Particular attention has been paid to published evidence from 2013 onwards, the last time the International Menopause Society recommendations were updated. Databases have been extensively searched for relevant publications using key terms specific to each specialist area within menopause physiology and medicine. Information has also been drawn from international consensus statements published by bodies such as the International Menopause Society, the European Menopause and Andropause Society and the North American Menopause Society.The recommendations have been produced by experts derived mainly from the International Menopause Society, with the assistance of key collaborators where deemed advantageous. In preparing these international recommendations, experts have taken into account geographical variations in medical care, prevalence of diseases, and country-specific attitudes of the public, medical community and health authorities towards menopause management. The variation in availability and licensing of menopause hormone therapy and other products has also been considered.

Insufficient luteal phase: laboratory diagnostic aspects. Opinion of Practice Committee of the American Society for Reproductive Medicine

Abstract: Insufficient luteal phase is considered today as one of the causes of miscarriage and infertility. Traditional methods of diagnostics of this condition are mainly based on laboratory methods. The article describes the possibilities of laboratory diagnostics of luteal phase deficiency, based on the updated opinion of Practice Committee of the American Society for Reproductive Medicine (ASRM) by 2015. Various methods are used for the luteal phase deficiency diagnostics, most of them are laboratory tests: evaluation of basal body temperature (experts of the American Society for Reproductive Medicine propose to treat it as already a historical criterion, taking into account all difficulties and convenience for the patient); evaluation of luteinizing hormone level in urine and assessment of the luteal phase duration; evaluation of progesterone levels in the blood; endometrial biopsy with histopathological examination. Each method has its own possibilities and limitations in the diagnostics of luteal phase deficiency that must be considered when results are interpreting. One of the most common methods used for the luteal phase deficiency diagnostics is test for serum progesterone level. It is important to remember high progesterone variability (8-fold concentration fluctuation within 90 min); no global standardization in the progesterone level, minimum necessary to ensure fertility; possible fluctuations in the hormone content in different cycles; strict definition of the day of progesterone test – 6–8 days after ovulation. At evaluation the luteinizing hormone level in urine it is necessary to determine the peak secretion (ovulation) and the luteal phase length. With its duration of 11–13 days confirmed the normal menstrual cycle, 8 days or less – a short luteal phase of the menstrual cycle. Detection of endometrial maturation disorders by biopsy today is traditionally regarded as one of the standard of luteal phase deficiency diagnostics

Updated 2013 international menopause society recommendations on menopausal hormone therapy and preventive strategies for midlife health

Abstract: In 2013 International Menopause Society published Updated 2013 Recommendations on Menopausal Hormone Therapy and Preventive Strategies for Midlife Health. These Recommendations and the subsequent key messages therefore give a global and simple overview that serves as a common platform on issues related to the various aspects of hormone treatment, which could be easily adapted and modified according to local needs. In recommending the term «menopausal hormone therapy» was used to refer estrogen, progestogen and combined therapies.

Синдром поликистозных яичников. Официальное заявление Европейского общества эндокринологии

Abstract: Polycystic ovary syndrome (PCOS) is the most common ovarian disorder associated with androgen excess in women, which justifies the growing interest of endocrinologists. Great efforts have been made in the last 2 decades to define the syndrome. The presence of three different definitions for the diagnosis of PCOS reflects the phenotypic heterogeneity of the syndrome. Major criteria are required for the diagnosis, which in turn identifies different phenotypes according to the combination of different criteria. In addition, the relevant impact of metabolic issues, specifically insulin resistance and obesity, on the pathogenesis of PCOS, and the susceptibility to develop earlier than expected glucose intolerance states, including type 2 diabetes, has supported the notion that these aspects should be considered when defining the PCOS phenotype and planning potential therapeutic strategies in an affected subject.The NIH Experts Panel recommended the maintenance of the broad diagnostic criteria of Rotterdam, but focused on the need for specific identification of the phenotype of each patient. Four different phenotypes of PCOS are now identified: 1) hyperandrogenism (clinical or biochemical) and CA (H-CA); 2) hyperandrogenism and polycystic ovaries on ultrasound (PCOm) but with ovulatory cycles (H-PCOm); 3) CA and polycystic ovaries without hyperandrogenism (CA-PCOm); and, finally, 4) hyperandrogenism, CA and polycystic ovaries (H-CA-PCOm). This paper offers a critical endocrine on the debate on the definition of PCOS and summarises all major aspects related to aetiological factors, including early life events, potentially involved in the development of the disorder. Diagnostic tools of PCOS are also discussed, with emphasis on the laboratory evaluation of androgens and other potential biomarkers of ovarian and metabolic dysfunctions. We have also paid specific attention to the role of obesity, sleep disorders and neuropsychological aspects of PCOS and on the relevant pathogenetic aspects of cardiovascular risk factors. In addition, we have discussed how to target treatment choices based according to the phenotype and individual patient’s needs.